SMO and skin basal cell carcinoma: The outcome of these ongoing clinical trials with immune checkpoint inhibitors for the treatment of metastatic or unresectable BCC alone or in combination with SMO inhibitors will inform whether immunotherapy or combinatorial treatments can increase the efficacy and durability of the response in BCC patients.